Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II Study of OB756 Tablets in Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia
ChiCTR2500105524Phase 2Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bewintinib in myelofibrosis (MF), polycythemia vera (PV) and thrombocythemia (11 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Proportion of subjects with ≥35% spleen volume reduction at 24 weeks. Started Jul 2025; status: completed.
02
Drugs
bewintinib
03
Conditions
myelofibrosis (MF)polycythemia vera (PV)thrombocythemia
Beyond the preview
Go deeper on ChiCTR2500105524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105524.